EBpay

Stock code: 002653.SZ

Innovation-driven Pipeline

The Company has more than 20 Class 1 innovative drug projects in clinical development across anesthesia and analgesia, respiratory diseases, chronic metabolic diseases, autoimmune diseases, oncology, and digestive and hepatic diseases. Five Class 1 innovative drugs are moving rapidly toward commercialization.
Anesthesia and Analgesia Respiratory Disease Chronic Metabolic Diseases Autoimmune Disease Oncology Others

SISHUNING®

SISHUNING® (HSK3486 Injection)

Target: Gamma-aminobutyric acid A receptor (GABAa)

Sedation and anesthesia for non-intubated surgical and diagnostic procedures

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SISHUNING® (HSK3486 Injection)

Target: Gamma-aminobutyric acid A receptor (GABAa)

Induction and maintenance of general anesthesia

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SISHUNING® (HSK3486 Injection)

Target: Gamma-aminobutyric acid A receptor (GABAa)

Sedation for patients on mechanical ventilation in intensive care

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SISHUNING® (HSK3486 Injection)

Target: Gamma-aminobutyric acid A receptor (GABAa)

Pediatric indications (China)

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SISHUNING® (HSK3486 Injection)

Target: Gamma-aminobutyric acid A receptor (GABAa)

Induction of general anesthesia (US)

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SIMEINING®

SIMEINING® (HSK16149 Capsules)

Target: Voltage-gated calcium channels (VGCC)

Diabetic peripheral neuropathic pain (DPNP)

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SIMEINING® (HSK16149 Capsules)

Target: Voltage-gated calcium channels (VGCC)

Postherpetic neuralgia (PHN)

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SIMEINING® (HSK16149 Capsules)

Target: Voltage-gated calcium channels (VGCC)

Central neuropathic pain

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SISHUJING®

SISHUJING® (HSK21542 Injection)

Target: Peripheral kappa-opioid receptor (KOR)

Postoperative analgesia after abdominal surgery

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

SISHUJING® (HSK21542 Injection)

Target: Peripheral kappa-opioid receptor (KOR)

Postoperative analgesia after orthopedic surgery

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

HSK36357

HSK36357

Target: AAK1

Neuropathic pain

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

HSK55718

HSK55718

Target: Nav1.8

Acute pain

IND

Phase 1

Phase 2

Phase 3

NDA

Launched

HSK51155

HSK51155

Target: Nav1.8

Migraine / Acute pain / Chronic pain

IND

Phase 1

Phase 2

Phase 3

NDA

Launched